Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Operative and oncological results and impact on treatment strategy of systematic renal tumor biopsy: Comparison between patients < and >75 years old.

Santy A, Basset V, Colleter L, Meria P, Desgrandchamps F, Verine J, De Kerviler E, Masson-Lecomte A, Mongiat-Artus P.

Urol Oncol. 2019 Dec 18. pii: S1078-1439(19)30482-X. doi: 10.1016/j.urolonc.2019.11.009. [Epub ahead of print]

PMID:
31864935
2.

[Is sarcopenia a morbi-mortality factor in the treatment of localized muscle-invasive bladder cancer?]

Fraisse G, Renard Y, Lebacle C, Masson-Lecomte A, Desgrandchamps F, Hennequin C, Bessede T, Irani J.

Prog Urol. 2020 Jan;30(1):41-50. doi: 10.1016/j.purol.2019.11.002. Epub 2019 Dec 6. French.

PMID:
31818689
3.

CD8+PD-1-ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G.

Dumont C, Jacquier A, Verine J, Noel F, Goujon A, Wu CL, Hung TM, Desgrandchamps F, Culine S, Carosella ED, Rouas-Freiss N, LeMaoult J.

Cancer Immunol Res. 2019 Oct;7(10):1619-1632. doi: 10.1158/2326-6066.CIR-18-0764. Epub 2019 Aug 26.

PMID:
31451484
4.

Salvage cryoablation for local recurrence of prostatic cancer after curative therapy.

Barat M, Colleter L, Mongiat-Artus P, Jolibois Z, Quero L, Hennequin C, Desgrandchamps F, de Kerviler E.

Diagn Interv Imaging. 2019 Nov;100(11):679-687. doi: 10.1016/j.diii.2019.07.001. Epub 2019 Jul 19.

PMID:
31331832
5.

[Lower urinary tract disorders in men: which management?]

Desgrandchamps F.

Rev Prat. 2019 Mar;69(3):307-310. Review. French.

PMID:
30983260
6.

[Urogenital emergencies in dermatology].

Dauendorffer JN, Desgrandchamps F, Janier M, Bagot M, Fouéré S.

Ann Dermatol Venereol. 2019 Apr;146(4):307-310. doi: 10.1016/j.annder.2019.01.005. Epub 2019 Mar 2. French. No abstract available.

PMID:
30833031
7.

Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia.

Guilhen M, Hennequin C, Ouzaid I, Fumagalli I, Martin V, Guillerm S, Mongiat-Artus P, Ravery V, Desgrandchamps F, Quéro L.

Radiat Oncol. 2018 Oct 24;13(1):209. doi: 10.1186/s13014-018-1149-0.

8.

Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cells.

Desgrandchamps F, LeMaoult J, Goujon A, Riviere A, Rivero-Juarez A, Djouadou M, de Gouvello A, Dumont C, Wu CL, Culine S, Verine J, Rouas-Freiss N, Hennequin C, Masson-Lecomte A, Carosella ED.

Oncotarget. 2018 Sep 4;9(69):33160-33169. doi: 10.18632/oncotarget.26036. eCollection 2018 Sep 4.

9.

Peri-operative and local control outcomes of robot-assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score.

Fraisse G, Colleter L, Peyronnet B, Khene ZE, Mandoorah Q, Soorojebally Y, Bourgi A, De La Taille A, Roupret M, De Kerviler E, Desgrandchamps F, Bensalah K, Masson-Lecomte A.

BJU Int. 2019 Apr;123(4):632-638. doi: 10.1111/bju.14530. Epub 2018 Sep 27.

PMID:
30153399
10.

[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].

Michel C, Vordos D, Dumont C, Basset V, Meyer F, Gaudez F, Meria P, Cortesse A, Mongiat-Artus P, de la Taille A, Culine S, Desgrandchamps F, Masson-Lecomte A.

Prog Urol. 2018 Sep;28(10):495-501. doi: 10.1016/j.purol.2018.06.002. Epub 2018 Jul 8. French.

PMID:
29997033
11.

[Penile intra-epithelial neoplasia].

Dauendorffer JN, Renaud-Vilmer C, Cavelier Balloy B, Meria P, Desgrandchamps F, Bagot M.

Prog Urol. 2018 Sep;28(10):466-474. doi: 10.1016/j.purol.2018.05.008. Epub 2018 Jun 22. Review. French.

PMID:
29937064
12.

Insights for public education provided by French media on ideas about prostate cancer - A media analysis study.

Zanchetta MS, Cognet M, Lam-Kin-Teng MR, Dumitriu ME, Haag C, Kadio B, Desgrandchamps F, Rénaud L.

Health Promot Perspect. 2018 Apr 18;8(2):92-101. doi: 10.15171/hpp.2018.12. eCollection 2018.

13.

Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.

Robert G, Descazeaud A, Karsenty G, Saussine C, Azzouzi AR, de la Taille A, Desgrandchamps F, Faix A, Fourmarier M, Georget A, Benard A, Barry Delongchamps N.

World J Urol. 2018 Jun;36(6):921-929. doi: 10.1007/s00345-018-2193-y. Epub 2018 Jan 30.

PMID:
29383480
14.

Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.

Verine J, Colin D, Nheb M, Prapotnich D, Ploussard G, Cathelineau X, Desgrandchamps F, Mongiat-Artus P, Feugeas JP.

Am J Surg Pathol. 2018 Apr;42(4):423-441. doi: 10.1097/PAS.0000000000001025.

PMID:
29356723
15.

[Total or partial nephrectomy for renal tumors?]

Santy A, Masson-Lecomte A, Desgrandchamps F.

Rev Prat. 2018 Jan;68(1):48-51. French.

PMID:
30840387
16.

[Cryoablation under local anesthesia of renal tumors].

De Kerviler É, Colleter L, Masson-Lecomte A, Desgrandchamps F.

Rev Prat. 2018 Jan;68(1):45-47. French.

PMID:
30840386
17.

Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.

Rouas-Freiss N, LeMaoult J, Verine J, Tronik-Le Roux D, Culine S, Hennequin C, Desgrandchamps F, Carosella ED.

Oncoimmunology. 2017 Jul 5;6(9):e1342023. doi: 10.1080/2162402X.2017.1342023. eCollection 2017.

18.

Predictive factors for final pathologic ureteral sections on 700 radical cystectomy specimens: Implications for intraoperative frozen section decision-making.

Masson-Lecomte A, Francois T, Vordos D, Cordonnier C, Allory Y, Desgrandchamps F, de la Taille A, Saint F.

Urol Oncol. 2017 Nov;35(11):659.e1-659.e6. doi: 10.1016/j.urolonc.2017.06.053. Epub 2017 Jul 14.

PMID:
28716562
19.

[Morbi-mortality of transurethral resection of the prostate in patients aged 75 and over].

Evrard PL, Mongiat-Artus P, Desgrandchamps F.

Prog Urol. 2017 Apr;27(5):312-318. doi: 10.1016/j.purol.2017.02.005. Epub 2017 Apr 1. French.

PMID:
28377079
20.

[Localized prostate cancer: if not aggressive, tracking does not mean treating].

Desgrandchamps F, Masson-Lecomte A.

Rev Prat. 2017 Apr;67(4):361-363. French. No abstract available.

PMID:
30512875
21.

Risk factors of severe incisional hernia after renal transplantation: a retrospective multicentric case-control study on 225 patients.

Broggi E, Bruyère F, Gaudez F, Desgrandchamps F.

World J Urol. 2017 Jul;35(7):1111-1117. doi: 10.1007/s00345-016-1971-7. Epub 2016 Nov 15.

PMID:
27847971
22.

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.

Roperch JP, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C, Tubach F, Cussenot O, Incitti R.

BMC Cancer. 2016 Sep 1;16:704. doi: 10.1186/s12885-016-2748-5.

23.

Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).

Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C.

Int J Urol. 2016 Jul;23(7):572-9. doi: 10.1111/iju.13088. Epub 2016 Mar 11.

24.

Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4.

Wu CL, Svendsen SG, Riviere A, Desgrandchamps F, Carosella ED, LeMaoult J.

Hum Immunol. 2016 Sep;77(9):720-6. doi: 10.1016/j.humimm.2016.01.017. Epub 2016 Feb 10.

PMID:
26874236
25.

Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review.

Chawki S, Ploussard G, Montlahuc C, Verine J, Mongiat-Artus P, Desgrandchamps F, Molina JM.

PLoS One. 2015 Dec 7;10(12):e0144237. doi: 10.1371/journal.pone.0144237. eCollection 2015. Review.

26.

Efficacité et tolérance des injections intra-prostatique de toxine botulique dans le traitement de l'hyperplasie bénigne de prostate symptomatique : PHRC national PROTOX.

Robert G, Delongchamps NB, Descazeaud A, Bénard A, Azzouzi R, Saussine C, De la Taille A, Fourmarier M, Karsenty G, Desgrandchamps F, Faix A, Pasticier G, Bernhard J, Ferrière J, Ballanger P.

Prog Urol. 2015 Nov;25(13):853-4. doi: 10.1016/j.purol.2015.08.276. French. No abstract available.

PMID:
26544470
27.

Facteurs de risque d'éventration après transplantation ranale : étude rétrospective cas témoins bicentrique sur 230 patients.

Broggi E, Gaudez F, Desgrandchamps F, Bruyere F.

Prog Urol. 2015 Nov;25(13):764. doi: 10.1016/j.purol.2015.08.100. French. No abstract available.

PMID:
26544296
28.

The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.

Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C, Tubach F, Mentre F, Cussenot O, Grandchamp B.

Urology. 2015 Dec;86(6):1185-90. doi: 10.1016/j.urology.2015.07.036. Epub 2015 Sep 11.

PMID:
26364695
29.

18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer.

Quero L, Vercellino L, de Kerviler E, Mongiat-Artus P, Culine S, Merlet P, Ravery V, Meria P, Desgrandchamps F, Hennequin C.

Clin Nucl Med. 2015 Nov;40(11):e492-5. doi: 10.1097/RLU.0000000000000932.

PMID:
26252326
30.

Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review.

Oelke M, Speakman MJ, Desgrandchamps F, Mamoulakis C.

Urology. 2015 Oct;86(4):654-65. doi: 10.1016/j.urology.2015.06.025. Epub 2015 Jul 2. Review.

PMID:
26142712
31.

[Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences with cystectomy].

Benadiba S, Gauthier H, Ploussard G, Mongiat-Artus P, Froger L, Basset V, Pashootan P, Chartier E, Dadoun D, Jacob F, Ravery V, Culine S, Desgrandchamps F.

Prog Urol. 2015 Jul;25(9):549-54. doi: 10.1016/j.purol.2015.04.004. Epub 2015 May 26. French.

PMID:
26022236
32.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.

Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.

PMID:
25824720
33.

[Bladder cancer: interpretation of international recommendations].

Rivière A, Ploussard G, Desgrandchamps F.

Rev Prat. 2014 Dec;64(10):1415-9. French.

PMID:
25668833
34.

[Bladder cancer and urothelial tumors. New therapeutic strategies].

Desgrandchamps F, Hennequin C, Culine S.

Rev Prat. 2014 Dec;64(10):1363-4. French. No abstract available.

PMID:
25665313
35.

[Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia].

Descazeaud A, de La Taille A, Giuliano F, Desgrandchamps F, Doridot G.

Prog Urol. 2015 Mar;25(3):115-27. doi: 10.1016/j.purol.2014.12.003. Epub 2015 Jan 17. Review. French.

PMID:
25605342
36.

Bladder cancer in HIV-infected adults: an emerging concern?

Chawki S, Ploussard G, Montlahuc C, Verine J, Mongiat-Artus P, Desgrandchamps F, Molina JM.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19647. doi: 10.7448/IAS.17.4.19647. eCollection 2014.

37.

The feasibility of percutaneous renal cryoablation under local anaesthesia.

de Kerviler E, de Margerie-Mellon C, Coffin A, Legrand G, Resche-Rigon M, Ploussard G, Meria P, Mongiat-Artus P, Desgrandchamps F, de Bazelaire C.

Cardiovasc Intervent Radiol. 2015 Jun;38(3):672-7. doi: 10.1007/s00270-014-0995-x. Epub 2014 Sep 18.

PMID:
25231824
38.

Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort.

Pashootan P, Ploussard G, Cocaul A, de Gouvello A, Desgrandchamps F.

BJU Int. 2015 Jul;116(1):124-30. doi: 10.1111/bju.12931. Epub 2014 Dec 8.

39.

[Testicular tumors].

Legrand G, Ploussard G, Mongiat-Artus P, Desgrandchamps F, Culine S.

Rev Prat. 2014 Apr;64(4):557-60. French. No abstract available.

PMID:
24855796
40.

Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.

Ploussard G, Nicolaiew N, Mongiat-Artus P, Terry S, Allory Y, Vacherot F, Abbou CC, Desgrandchamps F, Salomon L, de la Taille A.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):157-62. doi: 10.1038/pcan.2014.2. Epub 2014 Feb 11.

PMID:
24513649
41.

Complement-binding anti-HLA antibodies and kidney-allograft survival.

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X.

N Engl J Med. 2013 Sep 26;369(13):1215-26. doi: 10.1056/NEJMoa1302506.

42.

Advocacy for renal biopsy based on two cases of mixed epithelial and stromal tumour.

Ingels A, Vérine J, Belle Mbou V, Desgrandchamps F, Tariel E, Mongiat-Artus P, Ploussard G.

Urol Int. 2014;92(1):116-8. doi: 10.1159/000348749. Epub 2013 May 25.

PMID:
23711728
43.

[Prostate cancer: interpretation of management guidelines].

Ploussard G, Desgrandchamps F.

Rev Prat. 2013 Apr;63(4):515-20. French.

PMID:
23682482
44.

[Should we treat prostate cancer?].

Desgrandchamps F, Hennequin C.

Rev Prat. 2013 Apr;63(4):465-8. French. No abstract available.

PMID:
23682466
45.

Kidney graft dysfunction in simultaneous pancreas-kidney recipients after pancreas failure: analysis of early and late protocol biopsies.

Viglietti D, Serrato T, Abboud I, Antoine C, Pillebout E, Busson M, Desgrandchamps F, Meria P, Godin M, Hurault de Ligny B, Thervet E, Legendre C, Suberbielle C, Verine J, Glotz D, Peraldi MN.

Clin Transplant. 2013 May-Jun;27(3):E249-55. doi: 10.1111/ctr.12095. Epub 2013 Feb 13.

PMID:
23406495
46.

[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l’homme de l’association française d’urologie.

Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French.

PMID:
23178093
47.

Prospective short-term evaluation of transurethral needle ablation procedure in an ambulatory setting.

Cornu JN, Desgrandchamps F, de la Taille A, Vicaut E, Aout M, Lukacs B.

Urol Int. 2012;89(4):451-6. doi: 10.1159/000342362. Epub 2012 Oct 26.

48.

Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F.

Expert Opin Pharmacother. 2012 Oct;13(14):2085-96. doi: 10.1517/14656566.2012.714368. Epub 2012 Aug 28. Review.

PMID:
22924980
49.

[Sexual dysfunctions linked with prostatic diseases].

Rouprêt M, Seisen T, De La Taille A, Desgrandchamps F.

Prog Urol. 2012 Jun;22 Suppl 1:S14-20. doi: 10.1016/S1166-7087(12)70030-1. French.

PMID:
22770495
50.

Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.

Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, Hong SJ, El Khalid S, Ratana-Olarn K; Reten-World Study Group.

BJU Int. 2012 Jan;109(1):88-95. doi: 10.1111/j.1464-410X.2011.10430.x. Epub 2011 Nov 25.

Supplemental Content

Loading ...
Support Center